Century Therapeutics (IPSC) EBIT (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly EBIT of -$23.7 million for Q1 2026, down 131.93% year-over-year from $74.2 million in Q1 2025, and down 14.69% quarter-over-quarter from -$20.7 million in Q4 2025.
Powered by 
Analysis
Century Therapeutics (IPSC) EBIT (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported EBIT for 7 consecutive years, with -$23.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 131.93% year-over-year to -$23.7 million; the TTM figure through Mar 2026 stood at -$115.1 million (down 252.58% YoY), while the FY2025 annual figure was -$17.3 million, up 87.5% from the prior year.
- EBIT retreated to -$23.7 million in Q1 2026 per IPSC's latest filing, from -$20.7 million in the prior quarter.
- Across five years, EBIT topped out at $74.2 million in Q1 2025 and bottomed at -$43.8 million in Q4 2023.
- Historically, EBIT has averaged -$27.0 million across 5 years, with a median of -$34.7 million in 2025.
- Annual changes were most pronounced in 2025 — EBIT soared 336.92% — and 2026, when it sank 131.93%.
- Century Therapeutics' EBIT stood at -$33.3 million in 2022, then sank by 31.39% to -$43.8 million in 2023, then advanced by 14.8% to -$37.3 million in 2024, then jumped by 44.61% to -$20.7 million in 2025, then fell by 14.69% to -$23.7 million in 2026.
- Business Quant data shows IPSC's EBIT at -$23.7 million in Q1 2026, -$20.7 million in Q4 2025, and -$36.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Century Therapeutics | 440.37 Mn | 180.29 Mn | - | -36.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -36.53 Mn |
| Mar 31, 2026 | -23.68 Mn |
| Dec 31, 2025 | -20.65 Mn |
| Sep 30, 2025 | -36.12 Mn |
| Jun 30, 2025 | -34.66 Mn |
| Mar 31, 2025 | 74.18 Mn |
| Dec 31, 2024 | -37.28 Mn |
| Sep 30, 2024 | -34.79 Mn |
| Jun 30, 2024 | -34.76 Mn |
| Mar 31, 2024 | -31.31 Mn |
| Dec 31, 2023 | -43.76 Mn |
| Sep 30, 2023 | -35.63 Mn |
| Jun 30, 2023 | -35.08 Mn |
| Mar 31, 2023 | -32.08 Mn |
| Dec 31, 2022 | -33.31 Mn |
| Sep 30, 2022 | -31.74 Mn |
| Jun 30, 2022 | -31.35 Mn |
| Mar 31, 2022 | -37.44 Mn |
| Dec 31, 2021 | -27.97 Mn |
| Sep 30, 2021 | -25.83 Mn |